{"organizations": [], "uuid": "7161c5a1be7db1092dcee123172a1a707f8e541a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://www.bio-medicine.org/inc/biomed/medicine-technology.asp", "section_title": "Latest Medical Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/medicine-technology-1/Ascletis-Secures-US-2435-Million-Financing-47916-1/", "country": "US", "title": "Ascletis Secures US$35 Million Financing", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "Ascletis Secures US$35 Million Financing", "spam_score": 0.0, "site_type": "news", "published": "2015-09-02T14:35:00.000+03:00", "replies_count": 0, "uuid": "7161c5a1be7db1092dcee123172a1a707f8e541a"}, "author": "", "url": "http://www.bio-medicine.org/medicine-technology-1/Ascletis-Secures-US-2435-Million-Financing-47916-1/", "ord_in_thread": 0, "title": "Ascletis Secures US$35 Million Financing", "locations": ["SHANGHAI"], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": ["Ascletis"], "text": "RSS Navigation Links HOME >> MEDICINE >> TECHNOLOGY Ascletis Secures US$35 Million Financing ... SHANGHAI Sept. 2 2015 /- Ascl...The proceeds from this financing will be used to expand Ascletis' pipe... With the support of the investors Ascletis is now entering an exciti... The proven track record of Ascletis' team together with its excellen... http://feeds.bio-medicine.org/latest-medical-technology Date:9/2/2015 \nSHANGHAI , Sept. 2, 2015 /PRNewswire/ -- Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore -based Pavilion Capital. The valuation of the Company before financing was US$300 million. \nThe proceeds from this financing will be used to expand Ascletis' pipeline, strengthen global development capabilities and enhance GMP commercial manufacturing. \n\"With the support of the investors, Ascletis is now entering an exciting new era. We're very happy that our accomplishments and potential are recognized by the investors. This financing provides the necessary capital to help us expand our pipeline,\" said Jinzi J. Wu , Ph.D., Ascletis' founder, President and CEO, \"Through internal R&D and global in-licensing efforts, Ascletis continues to develop innovative drugs to meet clinical needs in China as well as in the rest of the world.\" \n\"The proven track record of Ascletis' team, together with its excellent portfolio and clear strategy, creates a very compelling future,\" said Mr. Wei Fu , CEO of C-Bridge, commenting on the financing, \"We are pleased to participate in the exciting model Ascletis is developing, and look forward to assisting the company in pursuit of its vision, to bring breakthrough treatments to the Chinese market and to be a leading innovator in China .\" Mr. Wei Fu will join the board of the Company as a director. \nAscletis' triple therapy for hepatitis C, combining protease inhibitor ASC08 with interferon and ribavirin, successfully completed phase II study in Taiwan in the beginning of 2015. Ascletis is planning to start similar trial in China soon. On August 31, Ascletis ann '/>\"/>  9/1/2015)... BRUSSELS , Sept. 1, 2015 ... (Euronext Brussels: UCB) today announced top-line results from ... Compared with Teriparatide in postmenopaUsal women with osteoporosis ... bisphosphonatE therapy). The study (NCT01796301) met the primary ... of romosozumab in the percent change of total ... (Date:9/1/2015)... Sept. 1, 2015 Konica Minolta Medical Imaging ... (CR) system, designed to deliver enterprise level imaging to ... same Control Station as the Konica Minolta AeroDR wireless ... upgrade path from CR to DR. The SIGMA II ... improve workflow with unparalleled reliability and high capacity to ... (Date:9/1/2015)... , Sept. 1, 2015 UT Southwestern Medical ... distinguished faculty members joined U.S. Representatives Michael C. ... a roundtable discussion on the 21 st Century ... currently being considered by the United States ... including National Academy of Sciences members, department chairs, center ... [ 0 ] Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide [ 0 ] Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR [ 0 ] U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science ... Calif. , Feb. 15 Accuray Incorporated (Nasdaq: ... today that Mount Vernon Cancer Centre in the United Kingdom ... acquire a CyberKnife® Robotic Radiosurgery System. , The NHS has grown ... was born just over 60 years ago out of a long-held ... ... , RESEARCH TRIANGLE PARK, N.C. , ... CRO, has formed an exclusive team of India ,s ... The team consists of the best Minimal Access Surgeons in ... , Having already conducted multiple Minimally Invasive Device Trials ... Mount Vernon Cancer Centre Becomes First NHS Facility to Acquire a CyberKnife System Max Neeman International Expands Specialized Surgical Team for Clinical Trials (Date:9/2/2015)... ... 2015 , ... World Patent Marketing, a vertically integrated manufacturer ... that protects people from crime and other hostile situations. , \"The Security Services ... Creative Director of World Patent Marketing. \"The industry is growing at a healthy   ...   On September 9, 2015, ... doTERRA’s annual convention, the largest single-company convention to date for the state of Utah. ... forward to a tremendous event,” states David Stirling, doTERRA CEO. “One of the most   ...   Please join the world renowned ... which was established by the Foundation in 2007 with the help of Massachusetts ... more research remains our top priority,” commented Christine Buckley, Executive Director of the   ...   Mobile working is increasingly more important, ... seems that everywhere new mobile apps are being launched, and mobile device usage as ... regular part of their work and personal lives. What's more people are expecting mobile   September 01, 2015 , ... September is National Prostate Cancer ... affects more than 233,000 men each year in the United States. , Prostate cancer ... non-skin cancer in America, affecting 1 in 7 men. One new case occurs every ... [ 0 ] What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention [ 0 ] doTERRA to Host the Largest Single-Company Convention in the State of Utah [ 0 ] September Celebrated as Brain Aneurysm Awareness Month [ 0 ] New Mobility Experience From Winscribe [ 0 ] September is Prostate Cancer Awareness Month ... Inc. (NYSE: FRX ) today announced that ... the Company,s supplemental New Drug Application (sNDA) for Lexapro ... Major Depressive Disorder (MDD) in adolescents, 12 - 17 ... to be approved for the treatment of MDD in ... ... Finding could lead to new treatments for cognitive ... News) -- The human brain functions on \"the ... order and randomness, according to U.K.-based researchers who ... cognitive performance and psychiatric disorders. , The ... ... 20 CANTEL MEDICAL CORP. (NYSE: ... of the Company, to President and Chief Executive Officer. ... of Directors. Since joining Cantel in September 2004, Mr. Krakauer ... 2008 as President. The Board concurrently appointed Seth R. Segel, ... ... the Migraine Research Foundation (MRF) announced a new initiative ... migraine called FOR OUR CHILDREN. The new program ... understanding of migraine and its causes and treatments in ... , Migraine is very common in children - ... ... SEGUNDO, Calif., March 20 A former astronaut and ... a director of business development for Wyle,s Integrated Science ... Parazynski joins Wyle to assist in the company,s continued ... health and performance services to the Federal Government. He ... ... obscure clinical manifestation of severe vomiting sickness due to ... his colleagues at the Creighton University of Omaha, NE, ... of Gastroenterology . , Recent research into the neurobiology ... receptor types including two specific types that mediate neuropsychiatric ... Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents Human Brain Works Between Order and Chaos Cantel Medical Corp. Names Andrew Krakauer as CEO and Announces Other Corporate Appointments New initiative to support pediatric migraine research is announced Veteran Astronaut Joins Wyle Business Development Staff in Houston A severe vomiting sickness with chronic cannabis abuse ... the first commercially available real-time detection ... use. , ,The kit can detect ... genotypes of HPV providing the sensitivity ... simplifying the process by using a ... ACMI COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument.... ... An in vitro Nucleic ... Amplification using Microplate Chemiluminescence for ... Papillomavirus (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and ... DNA Lowand High-Risk Groups in ... An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...", "external_links": [], "published": "2015-09-02T14:35:00.000+03:00", "crawled": "2015-09-02T15:53:16.952+03:00", "highlightTitle": ""}